CIDRAP newsletters options
Two recent studies in Pediatrics look at risk factors for severe pediatric COVID-19 and COVID deaths in those younger than 21 years of age.
Many people who received Moderna and all who got J&J vaccines should receive a booster, advisers say.
Experts say antibiotic resistance is a "complex web of related problems" that will require a One Health response.
One study shows a 30% lower vaccination rate, and another higher rates of severe disease and death.
An estimated 80,000 to 180,000 healthcare workers died from COVID-19 in the pandemic's first 17 months.
A review of antibiotic prescribing at Veterans' Health Administration (VHA) mental health units found that only 1 in 10 patients were exposed to antibiotics, but urinary tract infections (UTIs) appeared to be frequently misdiagnosed, researchers reported today in Infection Control & Hospital Epidemiology.
COVID-19 vaccination does not increase the risk of miscarriage during the first trimester of pregnancy, according to a Norwegian case-control study that involved 13,956 women, 5.5% of whom were vaccinated against the virus. The results were published yesterday as a letter to the editor in the New England Journal of Medicine.
For the third week in a row, illness numbers in Europe rose, with a 7% jump last week.
Two large studies show very high protection against the more transmissible variant.
Officials are preparing to vaccinate up to 28 million US children aged 5 to 11 as soon as approval is granted.
Studies look at COVID-19 immune responses in pregnant women.
COVID-19 outpatients were more likely to have more respiratory symptoms if they were overweight or obese, according to a study published yesterday in Influenza and Other Respiratory Viruses.
The FDA may approve "mix and match" boosters, meaning different ones from the vaccine originally received.
The antibiotic SUL-DUR stacked up well to colistin for 28-day mortality and outperformed it for clinical cure rate and kidney harm.
France-based Valneva reports positive results for its vaccine compared with the AstraZeneca vaccine.
"Learnings from negative trials such as this are important."
COVID-19 patients with immune-mediated inflammatory diseases (IMIDs) may benefit from tumor necrosis factor (TNF) inhibitors, according to a study published yesterday in JAMA Network Open.
Out-of-pocket costs could range from $1,500 to $3,800, depending on insurance.
Elsewhere, countries in Eastern Europe are fighting surges, including Russia, Romania, Hungary, and Latvia.
Cold weather is likely driving more people inside in those states, leading to heightened virus transmission.
